Fredag 1 November | 00:59:18 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2025-08-22 09:00 Kvartalsrapport 2025-Q2
2025-05-08 09:00 Kvartalsrapport 2025-Q1
2025-02-20 09:00 Bokslutskommuniké 2024
2024-10-31 09:00 Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-05-08 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2024-05-07 - Kvartalsrapport 2024-Q1
2024-05-07 - Årsstämma
2024-02-22 - Bokslutskommuniké 2023
2023-10-31 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-26 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2023-05-25 - Årsstämma
2023-05-03 - Kvartalsrapport 2023-Q1
2023-02-23 - Bokslutskommuniké 2022
2022-11-02 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-30 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2022-05-27 - Årsstämma
2022-05-06 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-24 - Extra Bolagsstämma 2021
2021-10-20 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-28 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2021-05-27 - Årsstämma
2021-04-28 - Kvartalsrapport 2021-Q1
2021-02-17 - Bokslutskommuniké 2020
2020-11-03 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-28 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2020-05-27 - Årsstämma
2020-04-28 - Kvartalsrapport 2020-Q1
2020-02-17 - Bokslutskommuniké 2019
2019-10-31 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-06-04 - Årsstämma
2019-05-23 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2019-04-30 - Kvartalsrapport 2019-Q1
2019-02-15 - Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaNordic SME Sweden
SektorHälsovård
IndustriMedicinteknik
Lumito specialiserar sig på medicinsk teknik för digital patologi. Bolaget strävar efter att förbättra vävnadsdiagnostiken med sin patenterade teknologi baserad på uppkonverterade nanopartiklar. Bolaget planerar att initialt lansera sin första produkt för forskningslaboratorier. Bolaget bildades under 2010 som en spinoff från en forskargrupp vid Lunds universitets avdelning för atomfysik och lasercentrum. Lumito har sitt huvudkontor i Lund.
2023-11-27 15:35:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.

Lumito AB (publ) ("Lumito" or the "Company") has prepared an EU growth prospectus (the "Prospectus") for the forthcoming issue of units consisting of warrants with preferential rights for the Company's existing shareholders (the "Issue"), which the board of directors resolved on November 10, 2023, and announced the same day (changes to the terms and conditions for the Issue were resolved and announced on November 17, 2023). The Prospectus was approved and registered by the Swedish Financial Supervisory Authority today. The Prospectus, containing complete terms and conditions, is available on the Company’s website, www.lumito.se and will be made available on the Swedish Financial Supervisory Authority’s website, www.fi.se. Information about the Issue will be made available on the Company's and on Mangold Fondkommission AB:s website.

Time table

November 27, 2023Publication of the Prospectus
November 27, 2023Record date for receiving unit rights. Shareholders registered in the share register maintained by Euroclear Sweden AB on this day will receive unit rights for participation in the Issue
November 29, 2023 – December 8, 2023Trading in unit rights (UR) on NGM Nordic SME
November 29, 2023 – December 13, 2023Subscription period for the Issue
November 29, 2023 – Week 52, 2023Trading in paid subscribed units (BTU) on Nasdaq First North Premier Growth Market
December 15, 2023Estimated day for announcement of outcome

Advisers
Mangold Fondkommission AB is financial adviser and Advokatfirman Lindahl KB is legal advisor Lumito in connection with the Issue.